AbbVie Hepatitis C Treatment Shines In Latest Trials
Big pharma AbbVie (ABBV) released the first set of results from the phase-three trial of its new hepatitis C regimen Monday, sending AbbVie stock up 2% on the stock market today, near 49.40. The study found that after 12 weeks of treatment with three of AbbVie’s drug candidates plus standard oral drug ribavirin, 96% of patients showed a sustained viral response (SVR). The patients in this particular study, called Sapphire-1, all have genotype 1 of